1251P CHARIOT: A phase I dose escalation study combining ATR inhibitor Berzosertib with chemoradiotherapy in oesophageal cancer using time to event continual reassessment (TiTE-CRM) method: Results from A1 cohort (combination with palliative RT)
| Autor: | Mukherjee, S., Lord, S., Harman, R., McIntosh, D., Ooms, A., Parkes, M., Radhakrishna, G., Shaw, P.H., Hawkins, M.A. |
|---|---|
| Zdroj: | In Annals of Oncology September 2022 33 Supplement 7:S1120-S1120 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|